Background: It remains unclear whether anti-hypertensive medication use is associated with cognitive aging in general Chinese middle-aged and older adults, as well as the interplay with socioeconomic status (SES). We aim to examine associations of anti-hypertensive medication adherence, SES, and cognitive aging in Chinese middle-aged and older adults.

Methods: Our study was based on the China Health and Retirement Longitudinal Study, an ongoing longitudinal national survey recruiting community-dwelling adults aged ≥ 45 years. Baseline anti-hypertensive medication use was assessed at wave 1. Longitudinal adherence to anti-hypertensive medication was assessed during waves 1 and 2. SES was assessed using income, education, employment, and medical insurance. The annual rate of cognitive change was assessed using cognitive Z scores. Linear mixed models were used to examine longitudinal associations.

Results: A total of 9229 participants were included (mean [SD] age: 57.1 [8.9] years; men: 50.8%). After controlling for blood pressure and other characteristics, participants taking anti-hypertensive medication at baseline, compared to participants not using medication, had a significantly decelerated decline in global cognition (β = 0.014; 95% confidence interval [CI], 0.003 to 0.025 SD/year; P = 0.01) and memory (β = 0.021; 95% CI, 0.008 to 0.034 SD/year; P = 0.001), respectively. Similarly, participants with high anti-hypertensive medication adherence during follow-up had slower declines in global cognition (β = 0.014; 95% CI, 0.002 to 0.027 SD/year; P = 0.02) and memory (β = 0.023; 95% CI, 0.008 to 0.038 SD/year; P = 0.003), compared to the low adherence group. There were no significant differences in cognitive decline between hypertension participants using or persistently adhering to medication and normotension participants. The SES significantly interacted with anti-hypertensive medication in associations with cognitive aging, with more evident associations observed in low SES subgroup (all P for interaction < 0.05). Several sensitivity analyses were conducted, observing consistent findings.

Conclusions: Adhering to anti-hypertensive medication was associated with decelerated cognitive aging in Chinese community-dwelling middle-aged and older adults, especially in participants with low SES. These findings indicate that promoting anti-hypertensive medication use could be important to achieve healthy and inclusive cognitive aging in general Chinese middle-aged and older adults living with hypertension.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863513PMC
http://dx.doi.org/10.1186/s12916-025-03949-8DOI Listing

Publication Analysis

Top Keywords

anti-hypertensive medication
32
cognitive aging
16
medication adherence
12
middle-aged older
12
medication
9
anti-hypertensive
8
socioeconomic status
8
aging chinese
8
longitudinal study
8
chinese middle-aged
8

Similar Publications

The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.

View Article and Find Full Text PDF

Medication time of metformin and sulfonylureas and incidence of cardiovascular diseases and mortality in type 2 diabetes: a pooled cohort analysis.

Sci Rep

March 2025

Prevention of Metabolic Disorders Research Center, Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The effect of duration of medication with metformin and sulfonylurea (SUs) on cardiovascular diseases (CVD) and mortality events by duration of type 2 diabetes (DM) is unclear. This study aimed to investigate the effect of duration of treatment with metformin and SUs on CVD and mortality events based on DM duration in newly diagnosed DM patients. Data from three prospective cohorts of Tehran Lipid and Glucose Study (TLGS), Multi-Ethnic Study of Atherosclerosis (MESA), and Atherosclerosis Risk in Communities (ARIC) including 4108 newly diagnosed type 2 diabetes individuals (mean age, 59.

View Article and Find Full Text PDF

This study assesses the causal effects of antihypertensive and lipid-lowering drugs on inflammatory cytokines using a Mendelian randomization (MR) approach. We conducted a drug-targeted MR analysis using data from large-scale genome-wide association studies and eQTL datasets. SNPs near drug target genes served as instrumental variables to investigate the impact of antihypertensive (angiotensin-converting enzyme inhibitors [ACEIs], ARBs) and lipid-lowering drugs (HMGCR inhibitors, proprotein convertase subtilisin/Kexin type 9 [PCSK9] inhibitors, Niemann-Pick C1-like 1 inhibitors) on inflammatory cytokines.

View Article and Find Full Text PDF

Background: The prices of generic drugs in general are known to be higher in Korea than in other countries. However, it remains unknown whether the price levels of generic drugs in Korea relative to other countries can differ by therapeutic class. Therefore, this study compared the prices of generic drugs in four commonly used drug classes in Korea with those in other high-income countries.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the protective effects of bosentan, a dual endothelin receptor antagonist, against skeletal muscle ischemia-reperfusion injury (IRI) in rats.

Methods: A total of 24 male Wistar Albino rats were divided into four groups: control (C, n=6), bosentan-treated (B, n=6), ischemia-reperfusion (IR, n=6), and bosentan plus ischemia-reperfusion (B+IR, n=6). Bosentan (10 mg/kg) was administered 30 minutes prior to reperfusion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!